<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320982</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-8273-10-MW-CTIL</org_study_id>
    <nct_id>NCT01320982</nct_id>
  </id_info>
  <brief_title>Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder</brief_title>
  <acronym>MAP-S-01</acronym>
  <official_title>A Randomized Trial Administering Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo as add-on to Antipsychotics in Patients With Schizophrenia or Schizoaffective Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the efficacy of Pramipexole, Minocycline and
      Aspirin compared to placebo, as add-on to anti-psychotics in the treatment of patients with
      schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inflammatory processes have been implicated as a cause of schizophrenia (Fan, Goff et al.
      2007), and the COX-2 inhibitor, Celecoxib, has been shown to reduce symptoms of schizophrenia
      (Muller, Krause et al. 2010). Aspirin, which is also a non-steroidal anti-inflammatory
      drug(NSAID), irreversibly inhibits Cyclooxygenase-1 (COX-1) and modifies the enzymatic
      activity of Cyclooxygenase-2 (COX-2), thus inhibiting the formation of prostaglandins and
      reduces inflammatory reaction. In a study funded by the Stanley Medical Research Institute
      (SMRI) recently published, Laan at all (Laan, Grobbee et al. 2010) administered add-on
      1000mg/d of Aspirin to patients with schizophrenia receiving anti-psychotics, and reported
      reductions in Positive and negative syndrome scale (PANSS) total and PANSS positive scores
      without substantial side effects.

      Minocycline is a second-generation tetracycline that exerts anti-inflammatory and
      antimicrobial effects while having a distinct neuroprotective profile. Minocycline effects
      the glutaminergic system, through inhibition of neuronal nitric oxide synthase (nNOS) and
      blocking of nitric oxide (NO)- induced neurotoxicity (Du et al, 1998; Jiang et al., 2005),
      and thus has been suggested as a potential treatment for schizophrenia. One published study
      (Levkovitz, Mendlovich et al. 2010), and another, unpublished study by Bill Deakin found that
      add-on treatment of 200mg/d of Minocycline was beneficial for symptoms and cognition in
      schizophrenia, and a study by Miayoka et al (Miyaoka, Yasukawa et al. 2008) administered
      open-label 450 mg/day Minocycline, and found improvement on positive symptoms.

      Indirect pharmacological evidence suggests a relative excess of dopaminergic activity as
      being implicated in the pathogenesis of some of the symptoms of schizophrenia, and all
      effective antipsychotics effect dopamine D2 receptors. Pramipexole is a pre-synaptic dopamine
      auto-receptor agonist hypothesized to improve in symptoms in schizophrenia patients. In an
      open label study, Kasper at all (Kasper, Barnas et al. 1997) showed statistically significant
      improvement in PANSS scores in patients not stabilized on haloperidol. Other data indicate
      that add-on Pramipexole improves symptoms of depression and cognition, in patients with
      affective disorders (Goldberg, Frye et al. 1999; Sporn, Ghaemi et al. 2000; Goldberg, Burdick
      et al. 2004; Zarate, Payne et al. 2004), and Malhotra et al, unpublished data.

      All of these studies were relatively small, and were performed by investigators with an
      interest in the compound. The objective of this study is to replicate them in large trial by
      investigators with no specific interest in the compounds. This proposed study is a multi-arm
      study, in which patients will be randomized to one of the three study drugs: Pramipexole,
      Minocycline and Aspirin, or placebo as part of the same protocol. A design by which several
      active compounds are all compared to the same placebo arm has been utilized before for
      schizophrenia (Meltzer, Arvanitis et al. 2004). This design has several advantages: in
      addition to reduced costs and time it exposes fewer patients to placebo, and enables direct
      comparison between the compounds and not only to the placebo.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)total score</measure>
    <time_frame>Positive and Negative Syndrome Scale (PANSS) total score at week 8</time_frame>
    <description>Change from baseline in Positive and Negative Syndrome Scale (PANSS)total score at 8 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)total score</measure>
    <time_frame>Positive and Negative Syndrome Scale (PANSS) total score at week 16</time_frame>
    <description>Change from baseline in Positive and Negative Syndrome Scale (PANSS)total score at 16 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Positive and Negative Syndrome Scale (PANSS)positive sub-scale score at week 2</time_frame>
    <description>Change from baseline in Positive and negative syndrome scale(PANSS) positive sub-scale scoreat 2 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Positive and Negative Syndrome Scale(PANSS) positive sub-scale score at week 4 .</time_frame>
    <description>Change from baseline in Positive and Negative Syndrome Scale(PANSS) positive sub-scale score at 4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Positive and negative syndrome scale(PANSS) positive sub-scale score at week 8.</time_frame>
    <description>Change from baseline in Positive and negative syndrome scale(PANSS) positive sub-scale score at 8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Positive and negative syndrome scale(PANSS) positive sub-scale score at week 16.</time_frame>
    <description>Change from baseline in Positive and negative syndrome scale(PANSS) positive sub-scale score at 16 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at week 2</time_frame>
    <description>Change from baseline in Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at 2 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at week 4</time_frame>
    <description>Change from baseline in Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at 4 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at week 8</time_frame>
    <description>Change from baseline in Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at week 16</time_frame>
    <description>Change from baseline in Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Positive and Negative Syndrome Scale (PANSS) general psychopathology sub-scale score at 2 weeks</time_frame>
    <description>Change from baseline in Positive and Negative Syndrome Scale (PANSS) general psychopathology sub-scale score at week 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Positive and Negative Syndrome Scale (PANSS) general psychopathology sub-scale score at week 4</time_frame>
    <description>Change from baseline in Positive and Negative Syndrome Scale (PANSS) general psychopathology sub-scale score at 4 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Positive and Negative Syndrome Scale (PANSS) general psychopathology sub-scale score at week 8</time_frame>
    <description>Change from baseline in Positive and Negative Syndrome Scale (PANSS) general psychopathology sub-scale score at 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Positive and Negative Syndrome Scale (PANSS) general psychopathology sub-scale score at week 16</time_frame>
    <description>Change from baseline in Positive and Negative Syndrome Scale (PANSS) general psychopathology sub-scale score at 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale-Severity (CGI-S)</measure>
    <time_frame>Clinical Global Impression Scale-Improvement (CGI-S) at week 2</time_frame>
    <description>Change from baseline in Clinical Global Impression Scale-Severity(CGI-S)at 2 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale-Severity (CGI-S)</measure>
    <time_frame>Clinical Global Impression Scale-Severity (CGI-S) at week 5</time_frame>
    <description>Change from baseline in Clinical Global Impression Scale-Severity(CGI-S)at 5 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale-Severity(CGI-S)</measure>
    <time_frame>linical Global Impression Scale-Severity(CGI-S) at week 8</time_frame>
    <description>Change from baseline in Clinical Global Impression Scale-Severity(CGI-S)at 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale-Severity(CGI-S)</measure>
    <time_frame>Change from baseline in Clinical Global Impression Scale-Severity(CGI-S) at week 12</time_frame>
    <description>Change from baseline in Clinical Global Impression Scale-Severity(CGI-S)at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale-Severity(CGI-S)</measure>
    <time_frame>Change from baseline in Clinical Global Impression Scale-Severity(CGI-S) at week 16</time_frame>
    <description>Change from baseline in Clinical Global Impression Scale-Severity(CGI-S)at 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale- Improvement (CGI-I)</measure>
    <time_frame>Clinical Global Impression Scale- Improvement (CGI-I) at week 2</time_frame>
    <description>Change from baseline in Clinical Global Impression Scale- Improvement (CGI-I)at 2 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale- Improvement (CGI-I)</measure>
    <time_frame>Clinical Global Impression Scale- Improvement (CGI-I) at week 5</time_frame>
    <description>Change from baseline in Clinical Global Impression Scale- Improvement (CGI-I)at 5 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale- Improvement (CGI-I)</measure>
    <time_frame>Clinical Global Impression Scale- Improvement (CGI-I)at week 8</time_frame>
    <description>Change from baseline in Clinical Global Impression Scale- Improvement (CGI-I)at 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale- Improvement (CGI-I)</measure>
    <time_frame>Clinical Global Impression Scale- Improvement (CGI-I) at week 12</time_frame>
    <description>Change from baseline in Clinical Global Impression Scale- Improvement (CGI-I)at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale- Improvement (CGI-I)</measure>
    <time_frame>Clinical Global Impression Scale- Improvement (CGI-I)at week 16</time_frame>
    <description>Change from baseline in Clinical Global Impression Scale- Improvement (CGI-I)at 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Assessment of Cognition in Schizophrenia (BACS)</measure>
    <time_frame>rief Assessment of Cognition in Schizophrenia (BACS)at week 8</time_frame>
    <description>Change from baseline in Brief Assessment of Cognition in Schizophrenia (BACS)at 8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Assessment of Cognition in Schizophrenia (BACS)</measure>
    <time_frame>Brief Assessment of Cognition in Schizophrenia (BACS)at week 16</time_frame>
    <description>Change from baseline in Brief Assessment of Cognition in Schizophrenia (BACS)at 16 weeks.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>minocycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>minocycline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pramipexole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pramipexole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acetylsalicylic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>acetylsalicylic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>minocycline</intervention_name>
    <description>minocycline 100 mg/bid</description>
    <arm_group_label>minocycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pramipexole</intervention_name>
    <description>pramipexole 0.125, 0.25, 0.5 and 0.75 mg/bid</description>
    <arm_group_label>pramipexole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylsalicylic acid</intervention_name>
    <description>acetylsalicylic acid 500mg/ bid</description>
    <arm_group_label>acetylsalicylic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo bid</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, 18-65 years of age, inclusive

          2. Females who are abstinent or practicing an established method of birth control (oral
             contraceptive tablets, hormonal implant device, hormone patch, injectable
             contraceptive, intrauterine device.

          3. Willing and able to provide informed consent, after the nature of the study has been
             fully explained

          4. Current DSM-IV-TR diagnosis of schizophrenia or schizoaffective disorder as confirmed
             by modified Structured Clinical Interview for DSM Disorders (SCID) and having had at
             least 2 prior schizophrenic episodes, or continually ill for at least 6 months.

          5. Symptoms: 4 (moderate) or above on Clinical Global Impression scale (CGI-S)and 4
             (moderate)or above score on two of the following four Positive and negative syndrome
             scale (PANSS) items: delusions, hallucinatory behaviors, conceptual disorganization or
             suspiciousness/ persecution, and/or a total PANSS negative symptoms score of 18.

          6. Must be on any antipsychotic drug, for at least 2 weeks prior to the baseline visit,
             at doses within the Patient Outcome Research Team (PORT) criteria, whenever possible.
             Patients receiving higher doses will have their records reviewed to insure that their
             dose is required and, if possible, will be stabilized on a lower dose prior to study
             entry.

          7. Inpatients or outpatients. Inpatients will be randomized 3 days or more after
             admission

        Exclusion Criteria:

          1. Unwilling or unable, in the opinion of the Investigator, to comply with study
             instructions

          2. Pregnant or breast-feeding

          3. Unstable medical disease (malignancy, poorly controlled diabetes, active ischemic
             cardiac disease, or cardiomyopathy, serious pulmonary disease, kidney disease,
             impaired liver functioning. History of hemorrhagic CVA or peptic ulcer disease.

          4. Patients treated with: any of the trial medications i.e. pramipexole/minocycline/
             acetylsalicylic acid, NSAIDs, anti-coagulants, sucralfate, cimetidine, amantadine,
             mexiletine.

          5. Likely allergy or sensitivity to raloxifene/pramipexole/minocycline/acetylsalicylic
             acid.

          6. At significant risk of committing suicide, or in the opinion of the Investigator,
             currently is at imminent risk of suicide or harming others.

          7. Patients with a current DSM-IV substance or alcohol abuse. Patients with a history of
             and/or current recreational use of cannabinoids or alcohol, and/or patients who smoke
             cigarettes can be included.

          8. Concurrent delirium, mental retardation, drug-induced psychosis, or history of
             clinically significant brain trauma documented by CT or MRI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Weiser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Weiser, MD</last_name>
    <phone>972-52-6666575</phone>
    <email>mweiser@netvision.net.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katya Rubinstein, MA</last_name>
    <phone>972-3-5303454</phone>
    <email>rubins.katya@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat-Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Weiser, MD</last_name>
      <phone>+972-52-6666575</phone>
      <email>mweiser@netvision.net.il</email>
    </contact>
    <contact_backup>
      <last_name>Katya Rubinstein, MA</last_name>
      <phone>+972-3-5303454</phone>
      <email>rubins.katya@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Weiser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica de Psihiatrie</name>
      <address>
        <city>Arad</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Delia Podea, MD</last_name>
      <phone>0722 583 757</phone>
      <email>deliapodea@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Delia Podea, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul de Psihiatrie Botosani, Sectia Psihiatrie</name>
      <address>
        <city>Botosani</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolae Vlad, MD</last_name>
      <phone>0741 335 034</phone>
      <email>v_nicolae@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Nicolae Vlad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie &quot;Prof. Dr. Alex. Obregia&quot;</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dan Prelipceanu, MD</last_name>
      <phone>0722 300 227</phone>
      <email>prelipceanudan@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Dan Prelipceanu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie &quot;Prof. Dr. Alex. Obregia&quot;</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriela Marian, MD</last_name>
      <phone>0723 569 620</phone>
      <email>gabi.marian@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Marian Gabriela, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie &quot;Prof. Dr. Alex. Obregia&quot;</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Ladea, MD</last_name>
      <phone>0724 371 042</phone>
      <email>marialadea@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Ladea, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie &quot;Prof. Dr. Alex. Obregia&quot;</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dorina-Valerica Sima, MD</last_name>
      <phone>0723 859 570</phone>
      <email>dorinasima@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Dorina-Valerica Sima, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie &quot;Prof. Dr. Alex. Obregia&quot;</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria-Silvia Trandafir, MD</last_name>
      <phone>0724 275 572</phone>
      <email>silviatrandafir2004@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Maria-Silvia Trandafir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie &quot;Prof. Dr. Alex. Obregia&quot;</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana-Liana Giurgiuca, MD</last_name>
      <phone>0722 378 967</phone>
      <email>giurgiuca_liana@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ana-Liana Giurgiuca, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie &quot;Prof. Dr. Alex. Obregia&quot;</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valentin Matei, MD</last_name>
      <phone>0723 640 918</phone>
      <email>petcu_camelia@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Valentin Matei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sp. Jud. &quot;Prof. Dr.O. Fodor&quot;</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mircea-Alexandru Birt, MD</last_name>
      <phone>0721 012 220</phone>
      <email>mirceabirt@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Mircea-Alexandru Birt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Cluj</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ioana-Valentina Miclutia, MD</last_name>
      <phone>0722 796 067</phone>
      <email>ioanamiclu@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ioana-Valentina Miclutia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie Socola, Iasi</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Serban Turliuc, MD</last_name>
      <phone>0745 203 002</phone>
      <email>serban_turliuc@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Serban Turliuc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie Socola, Iasi</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicoleta Cartas, MD</last_name>
      <phone>0724 576 261</phone>
      <email>nicoletacartas_socola@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Nicoleta Cartas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2011</study_first_submitted>
  <study_first_submitted_qc>March 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2011</study_first_posted>
  <last_update_submitted>March 22, 2011</last_update_submitted>
  <last_update_submitted_qc>March 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Mark Weiser MD (PI)</name_title>
    <organization>Sheba Medical Center</organization>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>schizoaffective disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

